Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Tarsus Pharmaceuticals, Inc. - Common Stock
(NQ:
TARS
)
80.10
-0.67 (-0.83%)
Streaming Delayed Price
Updated: 3:16 PM EST, Jan 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Tarsus Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
Next >
TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Combines High-Growth Momentum with a Favorable Technical Setup
↗
January 01, 2026
Via
Chartmill
TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Shows High-Growth Momentum and Technical Setup for Breakout
↗
December 10, 2025
Tarsus Pharmaceuticals (TARS) combines explosive revenue growth with a strong technical setup, presenting a potential breakout opportunity for momentum investors.
Via
Chartmill
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake?
↗
December 02, 2025
A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next.
Via
The Motley Fool
TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Shows Strong Technical Health and Growth Momentum
↗
November 22, 2025
Discover TARSUS PHARMACEUTICALS (TARS), a top growth stock with a perfect 10/10 technical rating and explosive 182% revenue growth, signaling strong upside potential.
Via
Chartmill
TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Shows Strong Growth Momentum and Technical Setup
↗
November 14, 2025
Discover Tarsus Pharmaceuticals (TARS), a high-growth stock with strong fundamentals and a bullish technical setup poised for a potential breakout.
Via
Chartmill
Earnings Scheduled For November 4, 2025
↗
November 04, 2025
Via
Benzinga
Earnings Scheduled For August 6, 2025
↗
August 06, 2025
Via
Benzinga
Earnings Scheduled For May 1, 2025
↗
May 01, 2025
Via
Benzinga
An Overview of Tarsus Pharmaceuticals's Earnings
↗
April 30, 2025
Via
Benzinga
Earnings Scheduled For February 25, 2025
↗
February 25, 2025
Via
Benzinga
Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase
↗
October 27, 2025
Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase
Via
The Motley Fool
Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares
↗
October 20, 2025
Via
The Motley Fool
3 Biotech Catalysts Present Major Opportunity
↗
August 25, 2025
Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further.
Via
MarketBeat
Top 2 Health Care Stocks That May Fall Off A Cliff In August
↗
August 20, 2025
Via
Benzinga
A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts
↗
January 27, 2025
Via
Benzinga
Earnings Scheduled For November 13, 2024
↗
November 13, 2024
Via
Benzinga
Earnings Outlook For Tarsus Pharmaceuticals
↗
November 12, 2024
Via
Benzinga
Analyst Ratings For Tarsus Pharmaceuticals
↗
May 09, 2024
Via
Benzinga
Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
↗
May 27, 2025
Via
Benzinga
6 Analysts Assess Tarsus Pharmaceuticals: What You Need To Know
↗
May 05, 2025
Via
Benzinga
Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal
↗
May 05, 2025
Elanco sells U.S. Xdemvy royalties to Blackstone for $295 million, aiming to lower debt and cut interest costs while retaining global rights.
Via
Benzinga
Would Mark Minervini consider TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) a top stock pick?
↗
April 23, 2025
Exploring high growth characteristics of TARSUS PHARMACEUTICALS INC (NASDAQ:TARS). A fundamental and technical analysis of (NASDAQ:TARS).
Via
Chartmill
Why Mark Minervini may look into TARSUS PHARMACEUTICALS INC (NASDAQ:TARS)
↗
April 01, 2025
A fundamental and technical analysis of (NASDAQ:TARS): Why the high growth investor may take a look at TARSUS PHARMACEUTICALS INC (NASDAQ:TARS).
Via
Chartmill
How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run
↗
December 26, 2024
The company sells one drug to treat a condition that causes dry, red and itchy eyes. But rosacea and Lyme disease could be next.
Via
Investor's Business Daily
Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday
↗
November 15, 2024
Via
Benzinga
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
↗
October 28, 2024
Via
Benzinga
TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
↗
August 08, 2024
TARS stock results show that Tarsus Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
May 13, 2024
Via
Benzinga
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
July 26, 2024
Via
Benzinga
Simple Ways To Stay With Trends: The Week In Charts
↗
May 12, 2024
Has the market made its all-time highs? In this video I cover the stock and crypto markets.
Via
Talk Markets
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
